Investment Q&A

Q: I am trying to understand what's going on with HHL this year. It's the worst performing ETF in my portfolio, down 12% YTD, almost double the drop of the US-listed VHT which is in my taxable portfolio. HHL is held in RRSP, so no capital loss :( I am wondering whether to keep it for the income, or drop it and buy another healthcare ETF hoping that the healthcare will eventually recover and ETF like VHT will likely recover faster than HHL. Due to underperforming healthcare ETFs, my portfolio allocation in healthcare is now down to 6.5% from the 8% target. Any suggestions/thoughts?

Q: What is driving the Argentines to greater strength lately compared to the Canucks? Thanks.

Q: Hello 5i

ARTG reported earnings last night and it appeared decent except I was surprised at the hedging of about 50% of sales at approximately $2800/oz and another 25% at approximately $3300/oz. When did these hedges come into effect? I think they last for the rest of 2026 and the $3300 hedges go into 2027? Even with the low AISC they are leaving a lot of money on the table it appears. Is that why it is down 5% today? Also they have a dividend planned to start in 2nd half of 2026. This would be a positive I would have thought. Would you consider this stock to be a buy, hold or sell at this point?

Thanks for your advice.

Regards,

Brendan

Q: Hello, at current prices is KITS, SHOP and LMN a buy, sell or hold. Please explain why.
Thanks

Q: Hi There,
Would you add to either of these today, and if so, which would you add to first?
Thanks,

Q: What do you think of Kneat's announcement today.
The market liked the news and ticked upward!

Thnx 5i
David

Q: Could you please break down NRG. I am looking at entering this sector with 1 or 2 names. Which would be your top 3 long term picks.

Thank you!

Q: Hi Team,
I'm thinking of selling my BEP.UN and BIP.UN to a more diversified Utilities/Infrastructure ETF like HUTS, UMVP or ZUT since I already have a 8% weight in BN and BAM. What do you think of that move?

Thanks

Benoit

Q: Morning 5i Team,
I currently hold both MCO and BLK and I am thinking moving selling MCO and put the money on BLK. Would like to get your thoughts on this intended move.
Thanks,
H

Q: Stantec and WSP seem to be consolidating at recent levels - are these "growthy" enough for a TFSA and if not, do you have alternatives in the Industrial space either in Canada or the US? Thanks!

Q: Has been lacklustre for a bit. What would you currently rank high-low as the top 5 small calls on CDN and US exchanges?

Q: What's happening with Kraken? It drops every day now. Was the big run up all for getting top price for raising money to make their purchase? What do you see for Kraken over the next 6 to 12months? How do you think the stock will perform over this period? What catalysts will make it move? Finally, are you still bullish on it?

Q: Can a bull market continue with poor breadth? It seems like only things related to AI are going up. When you examine the current market, do you feel it is healthy or is the fact that everyone is piling into semiconductors, memory etc.. creating risk and an unhealthy market? Thank you!

Q: Perhaps you guys can clarify. Got your email about the benchmark beaters and clicked through to the long list.

At the bottom of the list it said "if you want to know which of these, etc etc". Please subscribe.


How do I find out your secret list of stocks you would actually buy?

Thanks


Sheldon

Q: Hi,
Could you offer your thoughts on recent earnings and whether or you would be keen to own either of these stocks today. If there are other, more growth oriented options, I'd like to hear your suggestions. Either US or Canadian for a TFSA or RIF account.
Thanks - your advice is always much appreciated.
D

Q: Hi Team,
I have seen discussion on Mda earnings yet, what’s your take? Also Atz just reported and looking for your analysis there as well. Thanks

Shane

Q: For international exposure in my portfolio - what would you consider the best ETF's for this. I presently own VEU (at around 10% of the portfolio) as I already have about 35% of portfolio in the US. Are there better options to get international exposure? What percentage of international exposure outside the US would be a good target?
Thanks for all your insights.

Q: Your thoughts please on the Surge quarter?

Thx

Q: My international holdings (ex-US) currently include positions in Germany, broader Europe, and Japan. I am specifically considering initiating or adding to positions in China-focused ETFs, such as MCHI (MSCI China), FXI (FTSE China 50), and KWEB (China Internet).
I would appreciate your perspective on the following:
- Geopolitical Stability: Given what appears to be a more predictable and stable global posture from China relative to the current erratic US Administration , do you view Chinese equities as a viable "hedge" or a diversifying force against U.S. domestic policy risk?
- Trump is to meet Xi in Beijing May 14-15. Given the erratic nature of relations, is it more prudent to initiate positions now while valuations are compressed—particularly in KWEB, which remains down ~17% YTD—or wait for clarity following the meeting?
- ETF Selection: Between the broad exposure of MCHI, the large-cap/SOE focus of FXI, and the tech-heavy KWEB, which vehicle do you prefer for a 12-to-24 month horizon? Furthermore, are there other US-listed China ETFs (e.g., ASHR for A-shares) that you believe offer better risk-adjusted exposure? :ao:

Q: I request an update on my previous inquiry from January 28 regarding Abbott Laboratories (ABT). Following your previous comments, I maintained my position; however, the stock has since declined significantly—falling from ~$106 to the mid-$80s, an 18-20% drop in just three months.
I am becoming increasingly unclear as to what exactly ails this company. While management points to the long-term potential of the Exact Sciences acquisition and new product launches like Volt PFA, the market’s reaction suggests deep skepticism. Specifically, I am concerned about:
- Operational Execution: The recent Class I recall of the Libre 3 sensors and the cautious 2026 guidance revision (citing dilution and nutrition segment weakness) have made me dubious about current management’s ability to navigate these complexities.
- Regulatory & Policy Risk: I have growing concerns regarding erratic and unclear US government policies impacting the medical device industry. How much of this "policy noise" is structural versus temporary (if anyone can tell) ?
- Analyst Sentiment vs. Price Action: Despite the price collapse, the analyst community seems to remain largely "Buy" rated with high price targets. Given the clear "thesis/technical divergence," is this a case of analysts being behind the curve, or is the stock genuinely oversold?
I am no longer keen on redeploying capital into the same sector. Given these factors, would you continue to ride out this volatility for the remainder of 2026, or has the fundamental story deteriorated enough to warrant an exit? (held in tax-deferred account)
I look forward to your insights and updated perspective. :ao: